News

Looking at biomarkers PD-L1 and TMB in tandem can help predict a patient with NSCLC reaction to immunotherapy.

A label update from the FDA has approved a sBLA for romiplostim to include data demonstrating sustained platelet responses in adults with ITP.

By implementing a survivorship program at their cancer center, oncology nurses were able to improve the quality of life in patients with recurrent breast cancer.

The FDA has granted a priority review for Trastuzumab Deruxtecan to treat HER2-positive metastatic breast cancer based on the results from two new studies.

At the 2019 ESMO Congress, results for the MONALEESA-3 trial showed promise for patients with breast cancer and had many experts excited over its clinical implications.

In this month’s episode of CURE Talks Cancer Podcast: Nursing Edition, we had the chance to speak with Chasity M. Washington, MPH, CHES, on how the diversity in the workplace is important to cancer care.

A closer look at the genealogy of Utah's founders provided one expert with a data mine to help combat lung cancer.

Management of axillary lymph nodes in patients with breast cancer has undergone some positive changes, but more research is required to treat this patient population properly.

Partial-breast radiation may be more convenient for patients with breast cancer, and according to recent research, the outcomes aren’t much different than patients who had whole-breast radiation.

Patients with a higher likelihood to develop BRCA 1 or BRCA 2 mutations are slipping through the cracks, making testing for these mutations a vital part of any breast cancer treatment plan.

Even if survivors of pediatric neuroblastoma received treatment before 1 year old, they are still at risk for cognitive issues years later.

A study of patients with chronic lymphocytic leukemia looked into the role of treatment and disease itself in cognitive impairment.

Malnutrition is a potentially fatal adverse event that many patients undergoing treatment for cancer will face, but it's an adverse event that can be dealt with ahead of time during the first visit with an oncology nurse.

Here are the top 5 Oncology Nursing News stories for September 2019.

At the 2019 European Society for Medical Oncology, new study results showed promise for a frontline combination therapy for patients with newly diagnosed, advanced ovarian cancer.

After being diagnosed with essential thrombocythemia, former NHL referee Kerry Fraser did his best to maintain a positive attitude – and he says his oncology nurses played a huge role in that.

Atezolizumab, along with T-DM1, showed benefit for a subgroup of patients with breast cancer.

A phase III study found that adding 2 years of ovarian function suppression to tamoxifen extended disease-free survival in certain patients with hormone receptor-positive breast cancer.

Earlier today, the FDA approved daratumumab, in combination with other treatments, to treat patients with multiple myeloma that are eligible for autologous stem cell transplant.

Patients – and their caregivers too – should be key players in their multiple myeloma treatment planning.

While immunotherapy can be a life-saving approach for many patients with cancer, there are some cardiac adverse events that nurses should look out for.

Popular noninvasive colorectal cancer screening test, Cologuard, recently received permission from the FDA to expand its test.

Being an advocate might not only change your patients' lives but your life as well.

An expert discusses 2 new surgical treatments for breast cancer-associated lymphedema.

With the approval of 2 new JAK inhibitors for the management and treatment of myelofibrosis, the space is undergoing a new progression, with lots of questions left to answer.

A new study shows promising results for niraparib in the treatment of patients with ovarian cancer.

Sometimes, there's only so much you can do for patients in a clinical setting. But by sharing their stories and struggles, you can drive change that will affect their clinical treatment.

At the 2019 World Conference on Lung Cancer, an NSCLC expert weighed in on the usefulness of cell-free DNA-based testing versus traditional tissue testing for genomic sequencing.